2015
DOI: 10.1016/j.ijcard.2015.10.115
|View full text |Cite
|
Sign up to set email alerts
|

Cardiac cachexia: hic et nunc

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
65
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 45 publications
(65 citation statements)
references
References 208 publications
0
65
0
Order By: Relevance
“…101 Transition of sarcopenia in chronic heart failure to cardiac cachexia Sarcopenia in CHF may ultimately progress to cardiac cachexia, 102,103 which is associated with an extremely poor prognosis. [104][105][106] The current prevalence of cardiac cachexia has been estimated to be 10% in the current heart failure population, a significant improvement from earlier numbers of up to 40%, which is thought to be due to an improved treatment of heart failure itself. 107 However, other studies estimate a prevalence of 5-15% in CHF, and the mortality rates of patients with cachexia range from 10-15% per year in COPD through 20-30% per year in CHF and chronic kidney disease.…”
Section: Sarcopenia In Heart Failurementioning
confidence: 99%
“…101 Transition of sarcopenia in chronic heart failure to cardiac cachexia Sarcopenia in CHF may ultimately progress to cardiac cachexia, 102,103 which is associated with an extremely poor prognosis. [104][105][106] The current prevalence of cardiac cachexia has been estimated to be 10% in the current heart failure population, a significant improvement from earlier numbers of up to 40%, which is thought to be due to an improved treatment of heart failure itself. 107 However, other studies estimate a prevalence of 5-15% in CHF, and the mortality rates of patients with cachexia range from 10-15% per year in COPD through 20-30% per year in CHF and chronic kidney disease.…”
Section: Sarcopenia In Heart Failurementioning
confidence: 99%
“…Cardiac cachexia is a serious complication of CHF with a high morbidity and mortality, and is characterized by significant weight loss and muscle wasting [1, 2]. CHF-related muscle wasting is the result of an ongoing imbalance in the activation of anabolic and catabolic pathways [3, 5, 6]. This imbalance is caused by a series of immunologic, metabolic, and neuro-hormonal processes [2, 6, 7].…”
Section: Introductionmentioning
confidence: 99%
“…37 It seems that changes in the GH/IGF-1 axis may impact the anabolic/catabolic balance in cachexia. 4 Protein synthesis occurs through activation of serine/threonine protein kinase mammalian target of rapamycin (mTOR). Indeed, F I G U R E 2 A simplified model for possible roles of melatonin in cardiac cachexia.…”
Section: Melatonin and Igf-1 Signaling Regulationmentioning
confidence: 99%
“…Cachectic HF patients show increased plasma levels of catecholamines, cortisol, aldosterone and TNF-α compared to the patients without cachexia. 4 Several studies have found that melatonin reduces some neurohormones levels such as epinephrine, cortisol, and angiotensin II ( Figure 2). [22][23][24] Furthermore, it has been shown that the level of this hormone is reduced in chronic heart failure (CHF) patients.…”
mentioning
confidence: 99%